This study evaluates the safety and clinical activity of Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, as an immunotherapeutic target, in combination with pembrolizumab, a PD-1 monoclonal antibody, in advanced/metastatic NSCLC with LKB1 mutations. The gene discussed is ODC1; the disease is non-small cell lung carcinoma.